US2011118825A1PendingUtilityA1
Anti-angiogenic compositions and methods of use
Est. expiryJul 19, 2013(expired)· nominal 20-yr term from priority
A61P 9/14A61P 7/04A61P 35/00A61P 7/02A61P 9/10A61P 43/00A61P 9/00A61P 27/02A61P 1/04A61P 19/02A61P 1/16A61P 13/02A61P 11/00C07K 14/811A61K 31/555A61K 31/203A61K 31/4745A61K 31/136Y10S977/773A61K 33/30C08L 23/0853A61K 9/1658A61K 31/57A61K 38/57A61K 31/165A61K 9/7007A61L 2300/622A61K 31/525A61K 9/0048A61K 31/122A61K 31/702A61K 31/519A61K 9/1647A61K 9/1641C07C 233/64A61K 9/0051Y10S977/915A61L 31/145A61K 33/06A61L 2430/36A61K 9/14A61K 31/427A61K 31/426A61L 2300/606A61K 9/0019A61K 31/337A61K 9/1635A61K 31/565C08L 29/04C08L 2312/00C08L 67/04A61K 31/335A61L 2300/416A61K 45/06A61K 9/5146A61L 31/10C08L 2203/02A61K 33/00A61K 9/5031A61L 31/16A61K 31/185B82Y 5/00A61K 9/5153A61K 31/20A61K 33/24
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
Claims
exact text as granted — not AI-modified1 - 61 . (canceled)
62 . A stent, comprising a generally tubular structure, the surface of which is coated with a composition comprising:
(a) an anti-angiogenic factor; and (b) a polymeric carrier.
63 . The stent of claim 62 , wherein said anti-angiogenic factor is Anti-Invasive Factor.
64 . The stent of claim 62 , wherein said anti-angiogenic factor is retinoic acid and derivatives thereof.
65 . The stent of claim 62 , wherein said anti-angiogenic factor is selected from the group consisting of Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1 and Plasminogen Activator Inhibitor-2.
66 . The stent of claim 62 , wherein said anti-angiogenic factor is taxol.
67 . The stent of claim 62 , wherein said composition is formed into microspheres having an average size of between 0.5 to 200 um.
68 . The stent of claim 62 , wherein said polymeric carrier is poly(lactic-co-glycolic acid).
69 . The stent of claim 62 , wherein said polymeric carrier is polycaprolactone.
70 . The stent of claim 62 , wherein said polymeric carrier is polylactic acid.
71 . The composition of claim 62 , wherein said polymeric carrier is a copolymer of polylactic acid and polycaprolactone.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.